Lv51
965 积分 2021-04-16 加入
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review
11天前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
11天前
已完结
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
11天前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
11天前
已完结
Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience
11天前
已完结
Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
11天前
已完结
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
11天前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
11天前
已完结
Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics
11天前
已完结
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence
11天前
已完结
皖公网安备34019202002308
